 GAINESVILLE, Fla.--BUSINESS WIRE--Cyclo Therapeutics, Inc. Nasdaq: CYTH Cyclo Therapeutics or the Company, a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the commencement of its pivotal Phase 3 study TransportNPC evaluating Trappsol CycloTM, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for the treatment of 